Patient baseline characteristics, recurrence rate, and recurrence by initial site of thrombosis
| Characteristic . | Therapy, no. (%) . | P . | Overall, no. (%) . | ||
|---|---|---|---|---|---|
| Anticoagulant . | Antiplatelet . | Combined therapy . | |||
| Overall | 38 (27.3) | 43 (30.9) | 58 (41.7) | 139 | |
| Median (range) age at first thrombosis, y | 37 (22-75) | 46 (15-84) | 42 (15-65) | .011 | 43 (15-84) |
| Sex | .053 | ||||
| Female | 30 (78.9) | 23 (53.5) | 39 (67.2) | 92 (66.2) | |
| Male | 8 (21.1) | 20 (46.5) | 19 (32.8) | 47 (33.8) | |
| Ethnicity | .188 | ||||
| Asian | 3 (7.9) | 8 (18.6) | 2 (3.4) | 13 (9.4) | |
| Black | 2 (5.3) | 1 (2.3) | 3 (5.2) | 6 (4.3) | |
| White | 22 (57.9) | 26 (60.5) | 37 (63.8) | 85 (61.2) | |
| Middle Eastern | 0 (0.0) | 1 (2.3) | 0 (0.0) | 1 (0.7) | |
| Hispanic | 7 (18.4) | 2 (4.7) | 10 (17.2) | 19 (13.7) | |
| Not Reported | 4 (10.5) | 5 (11.6) | 6 (10.3) | 15 (10.8) | |
| Median (IQR) no. of CV risk factors | 2 (1-3.25) | 1 (1-2) | 1.5 (1.25-1.75) | .908 | 1 (1-2.25) |
| Location of initial thrombosis | .003 | ||||
| Cardiac | 2 (5.3) | 9 (20.9) | 5 (8.6) | 16 (11.5) | |
| Cerebral | 25 (65.8) | 33 (76.7) | 43 (74.1) | 100 (71.9) | |
| Other* | 11 (28.9) | 1 (2.3) | 10 (17.2) | 22 (15.8) | |
| Triple-positive aPL antibodies | 12 (31.6) | 17 (39.5) | 21 (36.2) | .757 | 50 (36.0) |
| Recurrence observed | |||||
| Location of initial thrombosis | |||||
| Cardiac (n = 16) | 1 (50) of 2 | 2 (22) of 9 | 0 (0) of 5 | 3 (20) of 16 | |
| Cerebral (n = 101) | 6 (24) of 25 | 13 (39) of 33 | 4 (9) of 43 | 23 (23) of 101 | |
| Other* (n = 22) | 2 (18) of 11 | 1 (100) of 1 | 0 (0) of 10 | 3 (14) of 22 | |
| All, % | 9 | 16 | 4 | 29 | |
| Characteristic . | Therapy, no. (%) . | P . | Overall, no. (%) . | ||
|---|---|---|---|---|---|
| Anticoagulant . | Antiplatelet . | Combined therapy . | |||
| Overall | 38 (27.3) | 43 (30.9) | 58 (41.7) | 139 | |
| Median (range) age at first thrombosis, y | 37 (22-75) | 46 (15-84) | 42 (15-65) | .011 | 43 (15-84) |
| Sex | .053 | ||||
| Female | 30 (78.9) | 23 (53.5) | 39 (67.2) | 92 (66.2) | |
| Male | 8 (21.1) | 20 (46.5) | 19 (32.8) | 47 (33.8) | |
| Ethnicity | .188 | ||||
| Asian | 3 (7.9) | 8 (18.6) | 2 (3.4) | 13 (9.4) | |
| Black | 2 (5.3) | 1 (2.3) | 3 (5.2) | 6 (4.3) | |
| White | 22 (57.9) | 26 (60.5) | 37 (63.8) | 85 (61.2) | |
| Middle Eastern | 0 (0.0) | 1 (2.3) | 0 (0.0) | 1 (0.7) | |
| Hispanic | 7 (18.4) | 2 (4.7) | 10 (17.2) | 19 (13.7) | |
| Not Reported | 4 (10.5) | 5 (11.6) | 6 (10.3) | 15 (10.8) | |
| Median (IQR) no. of CV risk factors | 2 (1-3.25) | 1 (1-2) | 1.5 (1.25-1.75) | .908 | 1 (1-2.25) |
| Location of initial thrombosis | .003 | ||||
| Cardiac | 2 (5.3) | 9 (20.9) | 5 (8.6) | 16 (11.5) | |
| Cerebral | 25 (65.8) | 33 (76.7) | 43 (74.1) | 100 (71.9) | |
| Other* | 11 (28.9) | 1 (2.3) | 10 (17.2) | 22 (15.8) | |
| Triple-positive aPL antibodies | 12 (31.6) | 17 (39.5) | 21 (36.2) | .757 | 50 (36.0) |
| Recurrence observed | |||||
| Location of initial thrombosis | |||||
| Cardiac (n = 16) | 1 (50) of 2 | 2 (22) of 9 | 0 (0) of 5 | 3 (20) of 16 | |
| Cerebral (n = 101) | 6 (24) of 25 | 13 (39) of 33 | 4 (9) of 43 | 23 (23) of 101 | |
| Other* (n = 22) | 2 (18) of 11 | 1 (100) of 1 | 0 (0) of 10 | 3 (14) of 22 | |
| All, % | 9 | 16 | 4 | 29 | |
IQR, interquartile range.
Describes initial acute arterial location that did not occur at cerebral or cardiac site.